Safety and efficacy of topical imiquimod use in allogeneic hematopoietic stem cell transplant recipients: a multicenter retrospective analysis
Published: 15 August 2025| Version 1 | DOI: 10.17632/2tncgrz4hh.1
Contributor:
Farrah EzzeddineDescription
Supplemental Table 1. Patient demographics and details of allogeneic HSCT for the patient cohort. Supplemental Table 2: Response rates and recurrence rates across various indications after imiquimod treatment in allo-HSCT recipients.
Files
Categories
Dermatology